Abstract
We have experienced Nd-YAG therapy for a total fo 53 early gastric carcinoma patients who had severe complications, between May. 1982 and September. 1986.
Excluding 9 patients who died, the 44 patients who were followed up in detail consisting of 53 lesions in total showed 47 lesions (88.6%) with no remaining malignant tissue. Mainly undifferentiated types of IIa+IIc or IIc+III, 16-20mm in diameter and in the mid-portion region showed remaining malignancy and recurrent lesions developed. 3 of these recurrent cases underwent operation. 3 cases plus 5 cases from a Nd-YAG therapy pilot study group underwent operation. These 3 operated cases which showed remaining malignancy allowed us to accurately determine the amount extent of irradiation and the optimum angle of beam incidence required for successful Nd-YAG therapy.
For patients with severe complications. Nd-YAG therapy should be the first choice for early gastric carcinoma.
